“John Hardy, PhD, University College London, London, UK, discusses some of the key areas where his team has made the most progress in the field of dementia. Prof. Hardy highlights the large specialist clinics available to his group enabling cross-disease genetic analysis. Across all neurodegenerative diseases, early-onset disease is associated with overproduction of the disease protein. Whereas, in late-onset neurodegenerative diseases, the fault lies with the protein degradation system. In each neurodegenerative disease, this damage results in different lesions. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.
John Hardy occasionally consults for Eisai and is on the SAB of the biotech Ceracuity.